News

High Mortgage Rates, Economic Uncertainty Rain On Spring Home-Buying Season

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Tesla Surges 10% Friday, On Track For 2025's Best Week As Robotaxi Hype Builds

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Tesla Surges 10% Friday, On Track For 2025's Best Week As Robotaxi Hype Builds

China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst

What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook

China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst

What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook

Bitcoin, Ethereum, XRP, Dogecoin Surging, But 'Choppy' Weekend Could Precede The Next Push

Analyst Upgrades Dow, Calls Capex Cut And Asset Sales Positive

Recent News

Comcast Faces Analyst Concerns Over Broadband Losses Despite Revenue And Peacock Gains

Rosenblatt analyst maintains Neutral rating on Comcast (CMCSA) due to subscriber loss, despite upside in revenues and EBITDA in Q1 earnings.

This Week In Cannabis: Trump's Reform Buzz Drives Stocks Up, RAW's Secret Factory, Global Shifts And More

Cannabis stocks rally, RAW opens its factory, Portugal leads EU exports, here's what happened this week.

'Seems Like Dumb And Dumber'—Ross Gerber Says The Stock Market Isn't Buying Any Of These 'Moves'

'This Is Not Really How I Pictured My Life At 30'—Air Force Vet Says He Works Retail For $18 An Hour And 'Feels Like A Loser'

US Restaurants Face Growth Hurdles As Macro Headwinds Mount, Says Analyst

Goldman Sachs flags ongoing risks for U.S. restaurants in 2025, with macro uncertainty, weak consumer sentiment, and tariff pressures weighing on growth.

Mobileye's Robotaxi Push Gains Speed With Uber And Lyft, But Analyst Cuts 2026 Forecast On Tariff-Led SuperVision Delays

Mobileye stock rises as analyst highlights robotaxi momentum with Uber and Lyft, but trims 2026 forecast on SuperVision delays tied to tariffs.

What's Going On With Summit Therapeutics Stock On Friday?

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Deal Dispatch: Jack In The Box To Dump Del Taco, Fyre Brand Hits Auction Block, Bertucci's Bites Bankruptcy Bullet (Again)

This week, deal pros have a lot to digest, including Bertucci's latest stumble plus Jack in the Box taking tacos to the auction block.

Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's decision on semaglutide shortage.

Coursera AI Strategy Wins Points With Analyst, But Market Jitters Linger

Coursera shares jump as JPMorgan lifts price target, citing strong AI-driven initiatives but urging consistent execution for future growth.

Palantir Stock Soars On Defense Deals: What's Going On?

Palantir Technologies have surged 19% this week, trading above $110 Friday afternoon. Investors have responded positively to a combination of geopolitical developments and major defense partnerships.

Farmers Wonder What Trump Meant In His 'Our Farmers Are Great' Truth Social Post—'You're Already Putting More Thought Into It Than He Did'

What's Going On With IonQ Stock Today?

IonQ shares edge lower despite unveiling $22M Chattanooga quantum hub with EPB to boost U.S. leadership in computing and networking.